care is relevant for most phase I participants based on their prognosis and symptom burden. On average, patients enrolled in phase I trials have a median survival of approximately 9 months. 41 – 43 In our cohort, 82% of patients died within 1 year of
Search Results
End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials
Ramy Sedhom, Amanda L. Blackford, Arjun Gupta, Kelly Griffiths, Janet Heussner, and Michael A. Carducci
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial
Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, Benoist Chibaudel, Lucile Bauguion, Leïla Bengrine-Lefevre, Daniel Lopez-Trabada Ataz, May Mabro, Jean-Philippe Metges, Denis Péré-Vergé, Thierry Conroy, Astrid Lièvre, Morgan Andre, Françoise Desseigne, François Goldwasser, Julie Henriques, Amélie Anota, and Pascal Hammel
significant impact on patients’ general and nutritional status, especially at an advanced stage, and a high symptom burden (including fatigue, pain, and anxiety/depression), affecting health-related quality of life (HRQoL) and ultimately survival. 8 Therefore
Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma
Marta Penas-Prado, Terri S. Armstrong, and Mark R. Gilbert
incurable; chronic sequelae of the disease in survivors are understudied; and patients need symptomatic interventions. Data are needed on symptom burden, quality of life, neurocognitive outcomes, and social outcomes, including financial burden. Participation
Association of Social Support With Overall Survival and Healthcare Utilization in Patients With Aggressive Hematologic Malignancies
P. Connor Johnson, Netana H. Markovitz, Tamryn F. Gray, Sunil Bhatt, Ryan D. Nipp, Nneka Ufere, Julia Rice, Matthew J. Reynolds, Mitchell W. Lavoie, Carlisle E.W. Topping, Madison A. Clay, Charlotta Lindvall, and Areej El-Jawahri
lymphoma (37.9%) and myelodysplastic syndrome/myeloproliferative neoplasm (19.9%). Overall, 8.8% (n=22) of patients had limited social support. Table 1. Patient Characteristics Healthcare Utilization, Symptom Burden, and Survival Among all
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, James Stevenson, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes
abdominal signs and symptoms, such as ascites, pain, distension, and an abdominal mass. 11 , 38 They often have a high symptom burden compared with patients who have other types of cancer. The diagnosis of PeM may be delayed, because symptoms are
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar
regarding the diagnosis, assessment of symptom burden, and selection of appropriate symptom-directed therapies continue to present challenges for hematologists and oncologists. 5 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPNs
Provision of Palliative Care and Pain Management Services for Oncology Patients
Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur, and Andreas Kopf
combined standard oncology and palliative care should be considered early in the disease process for patients with metastatic cancer and/or a high symptom burden. Meanwhile, the European Society for Medical Oncology (ESMO) formalized the relationship
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
with suspected MPM often have dyspnea and chest pain; they may also have pleural effusion, fatigue, insomnia, cough, chest wall mass, loss of appetite, and weight loss. 14 – 16 Patients with MPM often have a high symptom burden; therefore, supportive
Building the Palliative Care Evidence Base: Lessons From a Randomized Controlled Trial of Oxygen vs Room Air for Refractory Dyspnea
Thomas W. LeBlanc and Amy P. Abernethy
services constitute a specific high-level skillset that adds something important to the care of patients with advanced cancers or those who have a significant symptom burden. Although the PCO represents a giant leap forward for patients with cancer and
Patterns of Palliative Care Consultation Among Elderly Patients With Cancer
Eric J. Roeland, Daniel P. Triplett, Rayna K. Matsuno, Isabel J. Boero, Lindsay Hwang, Heidi N. Yeung, Loren Mell, and James D. Murphy
combined integration of palliative care with standard oncology care for any patient with metastatic cancer or high symptom burden. 10 Survey studies have found an increase in the availability of palliative care across the United States, 1 with a near 3
